Summary.-An antiserum to methotrexate has been produced in a sheep against a conjugate of ovalbumin and methotrexate (MTX) prepared using a water-soluble carbodiimide. The antibodies produced were specific for substances containing the 2,4-diamino pteridine structure. Naturally occurring folates did not interfere with the assay. A radioimmunoassay has been developed using this antiserum, which can be used to measure MTX concentrations of less than 1 ng/ml in biological samples without prior extraction. The concentrations of MTX in the blood and urine of patients following a single i.v. bolus injection and following oral administration of the drug have been measured. The published radioimmunoassays for MTX have been compared.
THE antifolate drug methotrexate (MTX) is extensively used in the treatment of various forms of neoplastic disease. The great improvement in antitumour therapy achieved with it in recent years has resulted not only from increased clinical experience, but also from a knowledge of the pharmacokinetics of the drug (Henderson et al., 1965a; Henderson, Adamson and Oliverio, 1965b; Huffman et al., 1973; Bischoff et al., 1971; Dedrick, Bischoff and Zaharteo, 1970) . The value of measuring the concentration of MTX in various body fluids during treatment has recently been shown by a number of workers (Bleyer, Chabner, and Ommaya, 1973; Freeman-Narrod et al., 1975; Frei et al., 1975; Shapiro, Young and Mehla, 1975) . The lack of convenient, sensitive and specific methods for measuring MTX is one reason why widespread monitoring of its concentration in blood is not carried out more often. Conventional assay techniques for the measurement of MTX have been available for a number of years (Freeman, 1957; Kinkade, V7ogler and Dayton, 1974; Rothenberg, 1965; Werkheiser, 1961; Arons et al., 1975; Fountain et al., 1953) but are not generally specific or sensitive enough to be suitable for clinical use. Recently radioimmunoassays (RIA) have been developed for MTX (Bohuon, Duprey and Boudene, 1974;  Levine and Powers, 1974;  Raso and Schreiber, 1975; Hendel, Sarek and Hvidberg, 1976;  Loeffler, Blum and Nelson, 1976) . These are eminently suitable both for pharmacokinetic studies and blood drug-level monitoring since, besides being fairly specific, they are sensitive enough to measure the drug in small volumes of sample without prior extraction, and sufficiently easy to perform for large numbers of specimens to be processed rapidly at a time.
This paper describes the development of a sensitive rapid RIA for MTX using Dextran-coated charcoal for phase separation, which is quick to perform and as sensitive or more sensitive than previously published techniques. Two clinical applications of the assay are illustrated and the method, especially its specificity, is compared with previously published radioimmunoassays. Iminmunization procedure.-Two New Zealand white rabbits were immunized with 1 mg conjugate in 0 5 ml sterile saline emulsified with 1 ml complete Freund's adjuvant, followed at weekly intervals with 3 x 0 5 mg conjugate in 0 5 ml sterile saline emulsified with 1 ml Marcol 52 adjuvant . The rabbits were bled from the marginal ear vein 10 days after the last injection and at monthly intervals thereafter.
Two sheep were immunized into 6 i.m. sites in the legs with 5 mg MTX-ovalbumin and 2 mg BCG vaccine in 1 ml sterile saline emulsified with 2 ml Marcol 52 adjuvant. One month later, 2 mg of the conjugate was injected in the same way. Blood was collected from the jugular vein 10 days after each injection and monthly thereafter. The blood was allowed to clot and serum separated and stored at 4°C with the addition of 0l1% sodium azide.
Radioimnmnunoassay procedure.-The buffer used throughout the procedure was 0 05 M phosphate, 0-1 M NaCl, pH 7-4, containing 040o0 gelatin. The protocol for both antiserum dilution curves and for standard curves is shown in Table I . OxfordR dispensers or a Compu-petR (Warner Diagnostics Ltd) were used for dilutions and additions. The amount of antiserum used for establishing standard curves was determined by antiserum dilution curves, and was that dilution which bound 5000 of the added label. Tritiated MTX (10 Ci/mmol) was stored at 4°C as a stock concentration of 1 nm in 2% NaHCO3. This solution was diluted with buffer, 1: 100, immediately before use, so that 1 pmol (454 pg) [3H]-MTX was added per tube. A solution of MTX (10 ng/ml: 22 nM) was lyophilized in 2-ml aliquots. An aliquot was reconstituted for each assay and diluted to give the appropriate standards. Three or 4 10-fold dilutions of each sample were prepared and the MTX concentration at each dilution measured in duplicate. Dextran-coated charcoal (DCC) was prepared by mixing overnight at 4°C a 25 g/l suspension of charcoal (Norit A) with an equal volume (200 ml) ofa 2-5 g/l suspension of Dextran T-70. The fines were removed by centrifugation and the DCC resuspended in 400 ml of buffer and stored at 4°C.
The reagents were added in the order indicated in Table I to LP3 plastic tubes (Luckham Ltd) the contents mixed and allow-ed to stand at room temperature for 50 min followed by 10 min in iced water. DCC was added, the tubes were mixed again and allowed to stand for a further 10 min. They were then centrifuged at 2500 rev/min for 5 min. A 200-1I aliquot of supernatant was taken from each tube for scintillation counting in an LKB Ultrobeta or a Packard Tricarb (2425) liquid scintillation counter.
RESULTS

Antiserum production
The (Table I) were, therefore, selected for convenience.
MTX added to serum, uirine and CSF could be recovered quantitatively without prior treatment or extraction of the sample (Table II) . Normal pooled sera to which MTX was added to give concentrations of 100 ng/ml (0.22 ,uM) and 1000 ng/ml (2.2 juM) were assayed on different (Fig. 4) . The antiserum HP/S/3 I IA appears to be directed at structures containing the 2,4-diamino substituted in proved pteridine ring, since all the substances c in all tested which possessed this structure it. MTX cross-reacted with it to a greater or lesser of the parent compound, and further removal of the para-amino benzoic acid residue to produce 2,4-diamino-6-methyl pteridine virtually abolished its abilitv
The importance of the N10-methyl group in the antigen-antibody reaction is indicated by the relatively low (19%) cross-reactivity between the aintiserum and aminopterin in which the N10 group is absent, and its greater cross-reactivity with N10-methvl folic acid than with folic acid itself.
Modification of the actual pteridine nucleus, such as occurs in 7-hydroxy MTX (an important metabolite of MTX during high-dosage treatment regimes (Jacobs et al., 1976) ) reduced antibodybinding very markedly. It may even have abolished it, since the reference preparation of 7-OH-MTX we had available was contaminated with small amounts of MTX, as shown by column chromatography on DEAE cellulose. Both 4-amino-N10-methyl pteroic acid and 2,4-diamino-6-methyl pteridine have been identified in the urine and faeces of several different species of animal following MTX administration. Their presence is thought more likely to be due to bacterial cleavage during enterohepatic circulation of the drug (Johns and Valerino, 1971; Valerino, 1972) than to endogenous metabolism. In man, 4-amino-N10-methyl pteroic acid is found in the urine 24-96 h after the administration of MTX, in amounts up to 30%o of the total dose MTX given. It is, however, not detectable at all during the first 24 h (Huffman et al., 1973) . Because of the cross-reactivity of 4-amino-N10-methyl pteroic acid in the MTX RIA of urine, samples collected more than 24 h after a single dose of MTX, or at any time during long-term MTX treatment, will give falsely high results for urinary MTX excretion. This potentially important cause of confusion has not been adequately recognized in the past, but is amenable to investigation by chromatographic separation of urinarv MTX and its metabolites before RIA. Work along these lines is currently in progress in our laboratory.
The .
Three different species have been used to raise antibodies for use in MTX RIA. The methods of immunization chosen have been intradermal and/or subcutaneous in all but the present study, in which the intramuscular route was employed. The final dilution of antibody used in the published assays varied from 1: 120 to 1: 18,000, but antibody avidity was reported in only two cases. The methods used to calculate avidity were different in the two cases, which might possibly account for the I 00-fold difference between them. Alternatively, the differences might be real and be reflected in the different sensitivity of the resultant assays.
The specificities of the antisera obtained were in general very similar. All the antisera were highly specific with regard to folic acid and its analogues, thereby permitting measurement of MTX in the presence of folates, even when these were deliberately elevated.
Cross-reactions of the antisera with known matabolites of MTX were not always reported. This is unfortunate since, for reasons already given, it is important to know which of the metabolites interfere with the assay.
Tritiated MTX was used as label in all the published methods, and the amount used was generally less than 1 ng [3H]-MTX per assay tube. Assays using gamma emitting 1251 (Diagnostic Biochemistry Inc.) or 75Se as labels (unpublished observations) are either available commercially or at an a dvanced stage of development, but details of the characteristics of these assays are not vet available. The sensitivity of all the published assays is similar and more than adequate for almost every clinical and experimental purpose.
All the published methods differ in detail amongst themselves but true comparisons of their reliability, accuracy, precision, cost-effectiveness and clinical usefulness can only be made by comparing the results obtained on identical samples distributed through an international quality control scheme, such as those now available for other drugs and compounds of biological interest.
